Genmab A (GMAB) Debt Ratio (2019 - 2026)
Genmab A (GMAB) posted Debt Ratio of 0.4 for Q1 2026, down 2.71% on a QoQ basis from 0.41 in Q4 2025, and up 1735.76% year-over-year from 0.02 in Q1 2025.
Genmab A (GMAB) Debt Ratio (2019 - 2026) Analysis & Trends
Genmab A's Debt Ratio history runs 4 years deep, the most recent figure standing at 0.4 for Q1 2026.
- Quarterly Debt Ratio rose 1735.76% year-over-year to 0.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.4 (up 1735.76% YoY) and the FY2025 annual result came in at 0.41, changed N/A from the prior year.
- Debt Ratio was 0.4 for Q1 2026 at Genmab A, down from 0.41 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.41 in Q4 2025 and bottomed at 0.02 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.40 |
| Dec 31, 2025 | 0.41 |
| Mar 31, 2025 | 0.02 |
| Sep 30, 2020 | 0.00 |
| Dec 31, 2019 | 12,038.58 |
| Sep 30, 2019 | 0.00 |